English▼

Remarkable Response in Refractory Multiple Myeloma After CAR-T Cell Therapy

Name: Mohamed H

Gender: Male

Age: 70

Nationality: Egypt

Diagnosis: Multiple myeloma

    Patient Profile Mr. Mohamed H., 70-year-old male from Egypt

    Initial Diagnosis Multiple myeloma with widespread skeletal involvement. Pre-treatment PET/CT (July 2024) showed extensive hypermetabolic bone lesions throughout the axial and appendicular skeleton, with multiple destructive lesions and a maximum SUV of 17.9, indicating highly active disease.

    Treatment After progressing on conventional chemotherapy, Mr. Mohamed sought advanced options and chose Bioocus for targeted CAR-T cell immunotherapy.

    Follow-up Results (September 2024 – only ~2 months post-therapy) Repeat whole-body PET/CT revealed:

    • Dramatic reduction in metabolic activity across nearly all previously active lesions
    • Many lesions completely resolved (no abnormal FDG uptake)
    • Maximum SUV dropped from 17.9 to 5.16
    • Only mild diffuse marrow uptake remained, consistent with post-treatment reactive changes
    • No new hypermetabolic foci in bone or soft tissue

    Mr. Mohamed became completely asymptomatic shortly after infusion. He reports regained strength, no bone pain, and a return to normal daily life — outcomes he describes as “a second chance.”

    “Before the pain was everywhere, and I thought this was the end. After the CAR-T treatment at Bioocus, I feel like a new person. The latest scan shows the cancer is almost gone. I am so grateful.” — Mr. Mohamed H.

    This case demonstrates the powerful potential of CAR-T therapy in achieving rapid and deep responses, even in elderly patients with advanced, heavily pre-treated multiple myeloma.